Nicotinamide Adenine Dinucleotide (NAD+) is a coenzyme found in every cell of the body, and one of the most important molecules in the biology of aging. It serves as the essential fuel for mitochondrial energy production, a critical cofactor for DNA repair, and a key signalling molecule in longevity-relevant pathways including sirtuins. Its decline with age is one of the most robust and reproducible findings in aging biology.
Understanding why NAD+ matters, how it declines, and how to restore it alongside targeted peptide therapy represents one of the most evidence-grounded approaches to longevity medicine available today.
What NAD+ Does and Why It Declines
NAD+ is required for:
- Mitochondrial energy production: The electron transport chain, which generates ATP (cellular energy), requires NAD+ as an electron carrier. Low NAD+ directly impairs energy production in every cell.
- Sirtuin activation: Sirtuins are a family of enzymes (SIRT1-7) that regulate gene expression, metabolic function, stress resistance, and DNA repair. Sirtuins consume NAD+ to function. Low NAD+ means low sirtuin activity.
- PARP function: PARP enzymes repair DNA damage and also consume NAD+. As DNA damage accumulates with age, PARP activity increases, further depleting NAD+ at the very time it is needed most.
- CD38 activity: CD38, an enzyme that increases with chronic inflammation, is a major NAD+ consumer. The inflammaging of aging creates a futile cycle of NAD+ depletion.
NAD+ levels decline by approximately 50% between the ages of 40 and 60 in human tissue. This decline is not uniform: brain and muscle tissue show particularly steep declines.
NAD+ Precursors: How to Restore NAD+ Levels
Direct NAD+ supplementation is ineffective because NAD+ cannot cross cell membranes efficiently. Instead, precursors that the body converts to NAD+ intracellularly are used:
- NMN (Nicotinamide Mononucleotide): The most studied precursor in longevity research. Directly converted to NAD+ via the Preiss-Handler pathway. Oral bioavailability is supported by published human pharmacokinetic data.
- NR (Nicotinamide Riboside): An alternative precursor with a strong evidence base. Shown to increase blood NAD+ levels in multiple human clinical trials.
- Niacin (Vitamin B3): A less direct precursor with more complex conversion steps. Less commonly used in longevity protocols due to flushing side effects at effective doses.
Human clinical trials with NMN and NR have demonstrated measurable increases in blood and tissue NAD+ levels, with associated improvements in physical performance, insulin sensitivity, muscle function, and vascular health.
Why Peptides and NAD+ Are Synergistic
NAD+ precursor therapy and peptide therapy address different but complementary aspects of biological aging:
| Mechanism | NAD+ Precursors | Longevity Peptides |
|---|---|---|
| Mitochondrial energy | Direct restoration | GH peptides support GH-driven mitochondrial biogenesis |
| DNA repair | PARP and sirtuin support | Epitalon supports telomere maintenance |
| Immune function | Some evidence | Thymosin Alpha-1 direct immune support |
| Hormonal decline | Indirect (sirtuin effects) | GH peptides directly restore GH/IGF-1 axis |
| Body composition | Indirect metabolic effects | Direct anabolic signalling |
| Circadian rhythm | Limited | Epitalon restores pineal melatonin |
The combination addresses aging more comprehensively than either approach alone.
Designing a NAD+ and Peptide Longevity Stack
A comprehensive longevity stack at Longegra typically includes:
Foundation Layer (everyone):
- NMN or NR (NAD+ precursor): Daily oral administration
- CJC-1295 and ipamorelin: GH axis restoration
Extended Layer (based on biomarker assessment):
- Epitalon: Telomere maintenance and pineal support (cyclical)
- Thymosin Alpha-1: Immune function support
- GHK-Cu: Tissue repair and anti-inflammatory signalling
Advanced Layer (for patients with specific longevity goals):
- MOTS-c: Mitochondrial signalling optimisation
- Additional metabolic optimisation based on metabolic panel findings
The appropriate combination is determined by baseline biomarkers: IGF-1, inflammatory markers, testosterone, DHEA-S, thyroid function, and a metabolic panel.
The Research Landscape
NAD+ precursor research has advanced rapidly in the past decade. Key human data points:
- A 2020 study showed NMN supplementation improved muscle insulin sensitivity in prediabetic women
- Multiple studies have confirmed NR safely raises blood NAD+ by 40 to 60% in healthy adults
- NMN has been shown to improve physical endurance in older adults
The combination of NAD+ precursors and peptides has less direct trial data because combination protocols are inherently harder to study, but the mechanistic rationale and individual evidence streams are strong.
Frequently Asked Questions (FAQs)
Both effectively raise NAD+ levels. NMN may be more efficiently converted to NAD+ in some tissues, particularly muscle. NR has more published human trial data overall. The choice between them is often based on individual response and tolerability. Longegra physicians can recommend the appropriate form based on your profile.
